Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Apellis Pharmaceuticals Inc's Business Segments
Apellis Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable Segment Aggregation Before Other Operating Segment
Total Revenue
$ 268
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable Segment Aggregation Before Other Operating Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $ 268 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product71.6%
- SYFOVRE56.2%
- Licensing and Other Revenue28.4%
- Empaveli Pegcetacoplan15.4%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 192 | 71.6% |
| SYFOVRE | $ 151 | 56.2% |
| Licensing and Other Revenue | $ 76 | 28.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Apellis Pharmaceuticals Inc dataset.
Description of Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc., founded in 2009, is a global biopharmaceutical company dedicated to developing innovative therapies to treat various chronic diseases. The company is headquartered in Waltham, Massachusetts, United States.
Apellis focuses on the discovery, development, and commercialization of novel therapeutic compounds to target complement-dependent diseases. The complement system is a part of the innate immune system that helps in the defense against pathogens, but dysregulation of this system can lead to various diseases.
The flagship product of Apellis is pegcetacoplan, a targeted C3 therapy. Pegcetacoplan is designed to inhibit the C3 protein, an integral part of the complement system, and helps in treating several complement-mediated diseases. It is administered subcutaneously, enabling convenient and easy usage for patients.
Apellis currently has multiple ongoing clinical trials investigating the efficacy and safety of pegcetacoplan in various indications. These include geographic atrophy (GA) secondary to age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and C3 glomerulopathy (C3G).
Geographic atrophy (GA) is a progressive and irreversible degenerative disease of the retina, leading to severe vision loss. Apellis aims to address this unmet medical need by developing an effective treatment for GA. The Phase 3 DERBY and OAKS trials are investigating the use of pegcetacoplan in GA patients, with promising results from earlier trials.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder characterized by the destruction of red blood cells. Apellis is evaluating the potential of pegcetacoplan as a monotherapy or in combination with other PNH treatments in its ongoing clinical trials.
Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) are rare renal diseases caused by deregulated C3 activation. Apellis aims to provide a targeted therapy option for these conditions using pegcetacoplan. The company is running Phase 2 trials to investigate the efficacy and safety of the drug in these indications.
Apellis is also actively involved in research and development to explore the potential of pegcetacoplan in other complement-mediated diseases like systemic lupus erythematosus (SLE), IgA nephropathy, and amyotrophic lateral sclerosis (ALS).
In addition to pegcetacoplan, Apellis also has a pipeline of other complement inhibitors in various stages of development. This diverse portfolio demonstrates the company's commitment to addressing unmet medical needs in complement-dependent diseases.
Apellis Pharmaceuticals Inc. has collaborations with leading academic institutions, medical centers, and regulatory agencies across the globe. These partnerships help expedite the development and commercialization of its innovative therapies.
Overall, Apellis Pharmaceuticals Inc. is at the forefront of developing targeted therapies for complement-dependent diseases, with a strong focus on improving the lives of patients suffering from these chronic conditions. The company's dedication to research, clinical development, and commercialization has the potential to revolutionize the treatment landscape in various therapeutic areas.
Apellis focuses on the discovery, development, and commercialization of novel therapeutic compounds to target complement-dependent diseases. The complement system is a part of the innate immune system that helps in the defense against pathogens, but dysregulation of this system can lead to various diseases.
The flagship product of Apellis is pegcetacoplan, a targeted C3 therapy. Pegcetacoplan is designed to inhibit the C3 protein, an integral part of the complement system, and helps in treating several complement-mediated diseases. It is administered subcutaneously, enabling convenient and easy usage for patients.
Apellis currently has multiple ongoing clinical trials investigating the efficacy and safety of pegcetacoplan in various indications. These include geographic atrophy (GA) secondary to age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and C3 glomerulopathy (C3G).
Geographic atrophy (GA) is a progressive and irreversible degenerative disease of the retina, leading to severe vision loss. Apellis aims to address this unmet medical need by developing an effective treatment for GA. The Phase 3 DERBY and OAKS trials are investigating the use of pegcetacoplan in GA patients, with promising results from earlier trials.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder characterized by the destruction of red blood cells. Apellis is evaluating the potential of pegcetacoplan as a monotherapy or in combination with other PNH treatments in its ongoing clinical trials.
Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) are rare renal diseases caused by deregulated C3 activation. Apellis aims to provide a targeted therapy option for these conditions using pegcetacoplan. The company is running Phase 2 trials to investigate the efficacy and safety of the drug in these indications.
Apellis is also actively involved in research and development to explore the potential of pegcetacoplan in other complement-mediated diseases like systemic lupus erythematosus (SLE), IgA nephropathy, and amyotrophic lateral sclerosis (ALS).
In addition to pegcetacoplan, Apellis also has a pipeline of other complement inhibitors in various stages of development. This diverse portfolio demonstrates the company's commitment to addressing unmet medical needs in complement-dependent diseases.
Apellis Pharmaceuticals Inc. has collaborations with leading academic institutions, medical centers, and regulatory agencies across the globe. These partnerships help expedite the development and commercialization of its innovative therapies.
Overall, Apellis Pharmaceuticals Inc. is at the forefront of developing targeted therapies for complement-dependent diseases, with a strong focus on improving the lives of patients suffering from these chronic conditions. The company's dedication to research, clinical development, and commercialization has the potential to revolutionize the treatment landscape in various therapeutic areas.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company primarily focused on developing innovative therapies for patients with rare diseases and serious conditions. The company is centered on treatments that address unmet medical needs, particularly in the realms of autoimmune and complement-mediated diseases. Below is an extensive breakdown of the key segments, products, and services offered by Apellis Pharmaceuticals.
1. Therapeutic Areas and Segments
Apellis Pharmaceuticals operates within several therapeutic areas that are critical to its mission. The key segments include:
- Ophthalmology: A significant focus for Apellis is on eye diseases, particularly those related to complement regulation. The companys pipeline includes therapies aimed at conditions like geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a progressive condition leading to loss of vision.
- Hematology: Apellis is also involved in the treatment of hematological disorders, particularly those where complement activation plays a role. Conditions like paroxysmal nocturnal hemoglobinuria (PNH) fall under this segment.
- Immunology: This segment encompasses various autoimmune diseases where complement dysregulation contributes to disease processes. The company is developing therapies that target specific pathways within the complement system to modulate immune responses.
Core Products
Apellis Pharmaceuticals has developed and commercialized a number of core products, including:
- Empaveli™ (pegcetacoplan): Approved as a treatment for adults with PNH, Empaveli is a targeted therapy that inhibits the complement cascade, specifically targeting C3. This drug represents a significant advancement over traditional complement inhibitors, providing a new mechanism of action for those suffering from this rare blood disorder.
- Syfovre® (pegcetacoplan injection): Marketed for the treatment of GA secondary to AMD, Syfovre is the first and only approved therapy specifically for this indication. It works by modulating the complement system to reduce vision loss associated with the disease. It has shown promise in clinical trials, demonstrating improved outcomes for patients affected by this condition.
Pipeline Development
Apellis Pharmaceuticals has a robust pipeline of investigational drugs, reflecting its commitment to addressing various diseases associated with complement dysregulation:
- Ongoing Clinical Trials: Apellis is conducting several clinical trials evaluating pegcetacoplan for other indications, including various autoimmune diseases. These studies aim to assess the efficacy and safety of the drug in broader patient populations.
- Combination Therapies: The company is exploring potential combination therapies that include pegcetacoplan and other agents to enhance treatment efficacy and patient outcomes for various conditions.
Research and Development (R&D)
Apellis emphasizes R&D as a core component of its strategy, continually investing in studies to explore the mechanisms of the complement system and discover new therapeutic targets. The R&D segment focuses on:
- Innovation: The development of drugs that uniquely modulate the complement pathway, providing therapies that target specific components of the immune system.
- Collaborations and Partnerships: Apellis seeks collaborations with academic institutions, research organizations, and other biopharmaceutical companies to share knowledge, access new technologies, and bolster its research capabilities.
Educational and Support Services
Beyond its pharmaceutical offerings, Apellis provides a range of educational resources and support services for healthcare professionals and patients:
- Patient Support Programs: Apellis has initiatives to assist patients in navigating treatment regimens, understanding their conditions, and accessing financial resources. These programs are designed to enhance adherence to treatment and improve quality of life.
- Healthcare Professional Education: The company conducts outreach to educate healthcare providers about its products, clinical data, and the science behind complement modulation. This includes webinars, conferences, and detailed educational materials.
- Clinical Resource Centers: Apellis may establish or partner with clinical resource centers that focus on the diseases it targets, offering a platform for clinical trials, patient education, and expert consultation.
Conclusion
Apellis Pharmaceuticals Inc. is distinguished by its pioneering role in complement inhibition therapies, reflecting a strong commitment to addressing serious and rare diseases with innovative treatments. Through its focused segments, leading products, ongoing research, and comprehensive support services, Apellis aims to make a significant impact on patient outcomes and redefine treatment paradigms in the diseases it targets.
1. Therapeutic Areas and Segments
Apellis Pharmaceuticals operates within several therapeutic areas that are critical to its mission. The key segments include:
- Ophthalmology: A significant focus for Apellis is on eye diseases, particularly those related to complement regulation. The companys pipeline includes therapies aimed at conditions like geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a progressive condition leading to loss of vision.
- Hematology: Apellis is also involved in the treatment of hematological disorders, particularly those where complement activation plays a role. Conditions like paroxysmal nocturnal hemoglobinuria (PNH) fall under this segment.
- Immunology: This segment encompasses various autoimmune diseases where complement dysregulation contributes to disease processes. The company is developing therapies that target specific pathways within the complement system to modulate immune responses.
Core Products
Apellis Pharmaceuticals has developed and commercialized a number of core products, including:
- Empaveli™ (pegcetacoplan): Approved as a treatment for adults with PNH, Empaveli is a targeted therapy that inhibits the complement cascade, specifically targeting C3. This drug represents a significant advancement over traditional complement inhibitors, providing a new mechanism of action for those suffering from this rare blood disorder.
- Syfovre® (pegcetacoplan injection): Marketed for the treatment of GA secondary to AMD, Syfovre is the first and only approved therapy specifically for this indication. It works by modulating the complement system to reduce vision loss associated with the disease. It has shown promise in clinical trials, demonstrating improved outcomes for patients affected by this condition.
Pipeline Development
Apellis Pharmaceuticals has a robust pipeline of investigational drugs, reflecting its commitment to addressing various diseases associated with complement dysregulation:
- Ongoing Clinical Trials: Apellis is conducting several clinical trials evaluating pegcetacoplan for other indications, including various autoimmune diseases. These studies aim to assess the efficacy and safety of the drug in broader patient populations.
- Combination Therapies: The company is exploring potential combination therapies that include pegcetacoplan and other agents to enhance treatment efficacy and patient outcomes for various conditions.
Research and Development (R&D)
Apellis emphasizes R&D as a core component of its strategy, continually investing in studies to explore the mechanisms of the complement system and discover new therapeutic targets. The R&D segment focuses on:
- Innovation: The development of drugs that uniquely modulate the complement pathway, providing therapies that target specific components of the immune system.
- Collaborations and Partnerships: Apellis seeks collaborations with academic institutions, research organizations, and other biopharmaceutical companies to share knowledge, access new technologies, and bolster its research capabilities.
Educational and Support Services
Beyond its pharmaceutical offerings, Apellis provides a range of educational resources and support services for healthcare professionals and patients:
- Patient Support Programs: Apellis has initiatives to assist patients in navigating treatment regimens, understanding their conditions, and accessing financial resources. These programs are designed to enhance adherence to treatment and improve quality of life.
- Healthcare Professional Education: The company conducts outreach to educate healthcare providers about its products, clinical data, and the science behind complement modulation. This includes webinars, conferences, and detailed educational materials.
- Clinical Resource Centers: Apellis may establish or partner with clinical resource centers that focus on the diseases it targets, offering a platform for clinical trials, patient education, and expert consultation.
Conclusion
Apellis Pharmaceuticals Inc. is distinguished by its pioneering role in complement inhibition therapies, reflecting a strong commitment to addressing serious and rare diseases with innovative treatments. Through its focused segments, leading products, ongoing research, and comprehensive support services, Apellis aims to make a significant impact on patient outcomes and redefine treatment paradigms in the diseases it targets.